Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In a new study, neuroscientists at Oxford University have found that raised blood pressure and diabetes in mid-life alter brain structure to slow thinking speed and memory.

Close up of multiple head and brain MRI imaging

Looking at results from 22,000 volunteers in the UK Biobank who underwent brain scanning, the scientists found that raised blood pressure and diabetes significantly impaired the brain’s cognitive functions, specifically the performance of thinking speed and short-term memory.

Masud Husain, Professor of Neurology and Cognitive Neuroscience at the Nuffield Department of Clinical Neurosciences and lead investigator of the study, said, ‘For blood pressure, every mm of pressure in your arteries counts – even in people who aren’t on any treatment. For people who are on treatment, systolic blood pressures above 140 mm were associated with lower cognitive performance. The higher the pressure, the worse it is.’

The full story is available on the Nuffield Department of Clinical Neurosciences website

This story is also featured on the University of Oxford website

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.